177 related articles for article (PubMed ID: 38330990)
1. Vaccines targeting
Dailey GP; Rabiola CA; Lei G; Wei J; Yang XY; Wang T; Liu CX; Gajda M; Hobeika AC; Summers A; Marek RD; Morse MA; Lyerly HK; Crosby EJ; Hartman ZC
Hum Vaccin Immunother; 2024 Dec; 20(1):2309693. PubMed ID: 38330990
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating
Kumar M; Salem K; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM
J Nucl Med; 2021 Apr; 62(4):500-506. PubMed ID: 32859700
[TBL] [Abstract][Full Text] [Related]
3. Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast Cancer.
Goldberg J; Qiao N; Guerriero JL; Gross B; Meneksedag Y; Lu YF; Philips AV; Rahman T; Meric-Bernstam F; Roszik J; Chen K; Jeselsohn R; Tolaney SM; Peoples GE; Alatrash G; Mittendorf EA
Cancer Res Commun; 2024 Feb; 4(2):496-504. PubMed ID: 38335301
[TBL] [Abstract][Full Text] [Related]
4. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
5. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance.
Li L; Lin L; Veeraraghavan J; Hu Y; Wang X; Lee S; Tan Y; Schiff R; Wang XS
Breast Cancer Res; 2020 Aug; 22(1):84. PubMed ID: 32771039
[TBL] [Abstract][Full Text] [Related]
7. Estrogen therapy induces an unfolded protein response to drive cell death in ER+ breast cancer.
Hosford SR; Shee K; Wells JD; Traphagen NA; Fields JL; Hampsch RA; Kettenbach AN; Demidenko E; Miller TW
Mol Oncol; 2019 Aug; 13(8):1778-1794. PubMed ID: 31180176
[TBL] [Abstract][Full Text] [Related]
8. Ligand-binding Domain-activating Mutations of ESR1 Rewire Cellular Metabolism of Breast Cancer Cells.
Zinger L; Merenbakh-Lamin K; Klein A; Elazar A; Journo S; Boldes T; Pasmanik-Chor M; Spitzer A; Rubinek T; Wolf I
Clin Cancer Res; 2019 May; 25(9):2900-2914. PubMed ID: 30733228
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing.
Ross DS; Zehir A; Brogi E; Konno F; Krystel-Whittemore M; Edelweiss M; Berger MF; Toy W; Chandarlapaty S; Razavi P; Baselga J; Wen HY
Mod Pathol; 2019 Jan; 32(1):81-87. PubMed ID: 30158597
[TBL] [Abstract][Full Text] [Related]
10. Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer.
Liang J; Ingalla ER; Yao X; Wang BE; Tai L; Giltnane J; Liang Y; Daemen A; Moore HM; Aimi J; Chang CW; Gates MR; Eng-Wong J; Tam L; Bacarro N; Roose-Girma M; Bellet M; Hafner M; Metcalfe C
Sci Transl Med; 2022 Sep; 14(663):eabo5959. PubMed ID: 36130016
[No Abstract] [Full Text] [Related]
11. Activating Mutations of ESR1, BRCA1 and CYP19 Aromatase Genes Confer Tumor Response in Breast Cancers Treated with Antiestrogens.
Suba Z
Recent Pat Anticancer Drug Discov; 2017; 12(2):136-147. PubMed ID: 28245776
[TBL] [Abstract][Full Text] [Related]
12. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
[TBL] [Abstract][Full Text] [Related]
13. Preexisting Somatic Mutations of Estrogen Receptor Alpha (
Dahlgren M; George AM; Brueffer C; Gladchuk S; Chen Y; Vallon-Christersson J; Hegardt C; Häkkinen J; Rydén L; Malmberg M; Larsson C; Gruvberger-Saal SK; Ehinger A; Loman N; Borg Å; Saal LH
JNCI Cancer Spectr; 2021 Apr; 5(2):. PubMed ID: 33937624
[TBL] [Abstract][Full Text] [Related]
14. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
[TBL] [Abstract][Full Text] [Related]
16. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.
Brett JO; Spring LM; Bardia A; Wander SA
Breast Cancer Res; 2021 Aug; 23(1):85. PubMed ID: 34392831
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.
Guttery DS; Page K; Hills A; Woodley L; Marchese SD; Rghebi B; Hastings RK; Luo J; Pringle JH; Stebbing J; Coombes RC; Ali S; Shaw JA
Clin Chem; 2015 Jul; 61(7):974-82. PubMed ID: 25979954
[TBL] [Abstract][Full Text] [Related]
19. Estrogen-induced miR-196a elevation promotes tumor growth and metastasis via targeting SPRED1 in breast cancer.
Jiang CF; Shi ZM; Li DM; Qian YC; Ren Y; Bai XM; Xie YX; Wang L; Ge X; Liu WT; Zhen LL; Liu LZ; Jiang BH
Mol Cancer; 2018 Apr; 17(1):83. PubMed ID: 29685157
[TBL] [Abstract][Full Text] [Related]
20. ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.
Gelsomino L; Gu G; Rechoum Y; Beyer AR; Pejerrey SM; Tsimelzon A; Wang T; Huffman K; Ludlow A; Andò S; Fuqua SAW
Breast Cancer Res Treat; 2016 Jun; 157(2):253-265. PubMed ID: 27178332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]